Diffuse glioma heterogeneity and its therapeutic implications
JG Nicholson, HA Fine - Cancer discovery, 2021 - AACR
Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …
characterized by minimally effective genotype-targeted therapies. Recent advances have …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015
QT Ostrom, H Gittleman, G Truitt, A Boscia… - Neuro …, 2018 - academic.oup.com
Background CBTRUS is a unique professional research organization that focuses
exclusively on providing high-quality statistical data on the population-based incidence of …
exclusively on providing high-quality statistical data on the population-based incidence of …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration
with the Centers for Disease Control and Prevention and the National Cancer Institute, is the …
with the Centers for Disease Control and Prevention and the National Cancer Institute, is the …
[HTML][HTML] Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Background Detection of the BRAF V600E mutation in pediatric low-grade glioma has been
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib …
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib …
Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma
J Gállego Pérez-Larraya, M Garcia-Moure… - … England Journal of …, 2022 - Mass Medical Soc
Background Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor
prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been …
prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration
with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the …
with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the …
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven
effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the …
effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration
with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute …
with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute …
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to
CNS Tumor Taxonomy) was established to evaluate and make practical recommendations …
CNS Tumor Taxonomy) was established to evaluate and make practical recommendations …
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas
Abstract Canonical (H3. 1/H3. 2) and noncanonical (H3. 3) histone 3 K27M-mutant gliomas
have unique spatiotemporal distributions, partner alterations and molecular profiles. The …
have unique spatiotemporal distributions, partner alterations and molecular profiles. The …